Startup profile · funding coverage
Ona Therapeutics funding, valuation and investors
Barcelona biopharma developing first-in-class ADCs targeting treatment-resistant breast and colorectal cancers.
Keep track of Ona Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$86.6M · June 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$87M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Barcelona, Spain
Investors in latest funding
Lead: Columbus Venture Partners , Mérieux Equity Partners
Other: COFIDES , Korys , Ysios Capital , Asabys Partners , Bpifrance , Alta Life Sciences
Overview
Ona Therapeutics, a spin-off from IRB Barcelona and ICREA based at the Barcelona Science Park, develops first-in-class antibody-drug conjugates (ADCs) for treatment-resistant cancers. Its patient-driven discovery platform identifies novel tumor-specific antigens linked to resistance biology, then engineers precision ADCs with optimized payloads and linkers. Lead program ONA-255 targets breast cancer with a differentiated mechanism aimed at improving therapeutic index versus earlier ADC approaches. Second program ONA-389 addresses colorectal cancer and is advancing toward first-in-human studies. Ona retains full worldwide commercial rights. In June 2026, the company closed an oversubscribed $86.6M Series B co-led by Columbus Venture Partners and Mérieux Equity Partners to fund its transition to a clinical-stage company.
Why Ona Therapeutics is interesting
Ona's oversubscribed $86.6M Series B funds clinical proof-of-concept for ONA-255 in breast cancer while advancing ONA-389 toward first-in-human — European biotech raising on differentiated ADC science, not platform hype.
Product & use cases
Ona Therapeutics engineers first-in-class antibody-drug conjugates against novel tumor antigens associated with treatment resistance — integrating biological insight, target validation, antibody engineering, and linker-payload optimization.
- Breast cancer patients with treatment-resistant disease unresponsive to existing ADCs or chemotherapy
- Colorectal cancer indications with significant unmet need via ONA-389 program
- Oncology pipelines seeking differentiated ADC targets beyond crowded HER2/TROP2 modalities
- European biopharma clinical development with retained global commercial rights
Key facts
- Series B (Jun 2026): oversubscribed $86.6M co-led by Columbus Venture Partners and Mérieux Equity Partners
- Lead program ONA-255 advancing toward clinical proof-of-concept in breast cancer
- ONA-389 colorectal ADC advancing toward first-in-human studies
- Spin-off from IRB Barcelona and ICREA; based at Barcelona Science Park (PCB)
- Retains full worldwide commercial rights to all assets
- Existing backers include Ysios Capital, Asabys Partners, Bpifrance, Alta Life Sciences
Funding history (newest first)
Series B
2026-06 $86.6M- Columbus Venture Partners (lead)
- Mérieux Equity Partners (lead)
- COFIDES (participant)
- Korys (participant)
- Ysios Capital (participant)
- Asabys Partners (participant)
- Bpifrance (participant)
- Alta Life Sciences (participant)
Source: https://ona-therapeutics.com/press-release/ona-therapeutics-raises-86m/
Competitive landscape
Edge: Patient-driven discovery platform targeting resistance-associated antigens — aims for improved therapeutic index versus first-generation ADCs through differentiated biology, not me-too payloads.
ADCs are oncology's hottest modality, but most programs chase the same targets. Ona's Series B on first-in-class science for resistant cancers — with full global rights retained — reflects investor appetite for differentiated European clinical biotech as exit markets reopen. Clinical proof-of-concept for ONA-255 is the near-term value inflection.
-
Daiichi Sankyo / AstraZeneca (Enhertu) incumbent
Dominant HER2 ADC franchise; Ona targets resistance biology with novel antigens rather than competing on established HER2 targets.
-
Gilead (Trodelvy) incumbent
TROP2 ADC approved in breast cancer; Ona ONA-255 pursues differentiated mechanism for resistant tumors.
-
Mersana Therapeutics direct
ADC platform company with multiple clinical programs; Ona focuses on first-in-class targets from resistance biology discovery.
-
Sutro Biopharma adjacent
ADC technology platform with site-specific conjugation; Ona emphasizes novel target discovery from patient-driven biology.
Notable stories
- Ona is a spin-off from IRB Barcelona and ICREA — originating from academic research on tumor-specific antigens linked to treatment resistance (GlobeNewswire, June 2026).
- Board additions from Columbus Venture Partners, Mérieux Equity Partners, and Korys accompanied the Series B — signaling transition from discovery-stage to clinical-stage governance (company press release).
Industries
Related funding articles
Venture Capital Tracker pieces that cover Ona Therapeutics's financing or category context.
FAQs about Ona Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.